<DOC>
	<DOCNO>NCT00779311</DOCNO>
	<brief_summary>This research study perform approximately 3 site associate Accelerated Community Oncology Research Network , Inc. ( ACORN ) . Approximately 45 subject take part study . In study , everyone receive dose mFOLFOX6 Avastin . There five group subject . Each group subject receive high dose Nexavar previous group . This continue subject group major side effect dose give . This sponsor determine high dose Nexavar use mFOLFOX6 AVastin ( call maximum tolerate dose MTD ) .</brief_summary>
	<brief_title>A Phase I Trial Evaluating mFOLFOX6 Avastin With Nexavar First-Line Treatment Metastatic Colorectal Cancer</brief_title>
	<detailed_description>This investigator-initiated , multicenter , network , Phase 1 , open-label , dose-ranging study . The maximum sample size 45 patient ( 30 patient determine MTD Phase I , additional 15 patient provide estimate progression free survival ) . All eligible patient receive mFOLFOX6 regimen full dose follow IV bevacizumab 5mg/kg Day 1 treatment cycle . Treatment cycle length 2 week ( Q2W ) . Sorafenib administer daily throughout treatment begin day 1 . Dose limit toxicity define grade 4 hematologic event grade 3 4 non-hematologic event occur cycle 1 2 attributable sorafenib combination . The following event exclude definition : grade 3 nausea and/or vomit responsive antiemetic ; grade 3 fever infection ; grade 3 diarrhea responsive antidiarrheal therapy . Three patient enrol dose level observe dose-limiting toxicity ( DLTs ) 2 cycle treatment . Dose escalation sorafenib depend number patient experience DLT ( ) follow : - If 0/3 patient experience DLT ( ) , 3 patient treat next high dose . - If 1/3 patient experience DLT ( ) , 3 patient enrol dose . If 1/6 patient treat dose experience DLT ( ) , next cohort treat next high dose . However , ≥2/6 patient experience DLT ( ) dose , MTD consider exceed . At point , 3 patient treat next low dose , unless 6 already treat low dose . - If ≥2/3 patient experience DLT ( ) dose , 3 patient enrol next low dose unless 6 patient already treat dose . Dose escalation continue MTD determine dose level complete . The MTD define dose ≤1 6 patient experience DLT ( ) , ≥2 6 patient experience DLT ( ) . If MTD Dose Level 2 ( low ) , study terminate patient enrol . Once MTD sorafenib combine mFOLFOX6 bevacizumab determine , additional 15 patient mCRC enrol extension Phase 1 study . These patient treat MTD sorafenib combination therapy ass PFS safety regimen first-line therapy mCRC . All patient eligible indefinite treatment absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>No prior chemotherapy metastatic disease . Histologically proven colorectal carcinoma . Measurable disease RECIST criterion . Age : least 18 year . ECOG performance status 0 1 study entry . Adequate bone marrow , liver renal function study entry assess follow : Hemoglobin &gt; 9.0 g/dL . ANC ≥1500/mm3 . Platelet count ≥100,000/mm3 . Total bilirubin ≤1.5 time x ULN . ALT AST ≤2.5 × ULN ( ≤5 × ULN patient liver involvement ) . Creatinine ≤1.5 × ULN . INR &lt; 1.5 PT/PTT within normal limit . Patients receive anticoagulation treatment agent warfarin heparin may allow participate discussion ACORN . For patient warfarin , INR measure prior initiation sorafenib monitor least weekly , define local standard care , INR stable . Women childbearing potential must negative serum urine pregnancy test perform within 7 day prior start treatment . Women childbearing potential men must agree use adequate contraception ( barrier method birth control ) prior study entry duration study participation . Patients use adequate birth control least 3 month last administration sorafenib . Ability understand willingness sign write informed consent . A sign informed consent must obtain prior study specific procedure . Prior use bevacizumab . Neuropathy ≥ Grade 2 per CTCAE v3.0 . Diarrhea ≥ Grade 2 per CTCAE v3.0 within 4 week study treatment start . ECOG performance status ≥ 2 . Proteinuria baseline : patient discover &gt; 2+ proteinuria baseline undergo 24 hour urine collection must demonstrate &lt; 1 gram protein 24 hour eligible . Active malignancy mCRC ( except nonmelanoma skin cancer ; situ carcinoma cervix ; situ carcinoma breast ) within last 5 year . Treatment radiotherapy within 2 week enrollment . Cardiac disease : Congestive heart failure &gt; Class II NYHA . Patients must unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month . Known brain metastasis . Patients neurological symptom must undergo CT scan/ MRI brain exclude brain metastasis . Cardiac ventricular arrhythmia require antiarrhythmic therapy . Uncontrolled hypertension define systolic blood pressure &gt; 150 mm Hg diastolic pressure &gt; 90 mm Hg , despite optimal medical management . Known human immunodeficiency virus infection chronic Hepatitis B C. Active clinically serious infection &gt; Grade 2 per CTCAE v3.0 . Thrombolic embolic event cerebrovascular accident include transient ischemic attack within past 6 month . Pulmonary hemorrhage/bleeding event ≥ Grade 2 per CTCAE v3.0 within 4 week study treatment start . Any hemorrhage/bleeding event ≥ Grade 3 per CTCAE v3.0 within 4 week study treatment start . Serious nonhealing wound , ulcer , bone fracture . Evidence history bleed diathesis coagulopathy . Major surgery , open biopsy significant traumatic injury within 4 week study treatment start ; fine needle aspiration central venous line placement chemotherapy administration within 7 day study treatment start . Use daily corticosteroid , St. John 's Wort , rifampin ( rifampicin ) , phenytoin , carbamazepine , phenobarbital , ketoconazole . Dexamethasone may use antiemetic premedication bevacizumab hypersensitivity reaction participation study . Known suspect allergy sorafenib agent give course trial . Any condition impair patient 's ability swallow whole pill . Any malabsorption problem .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
</DOC>